Search | IOVS | ARVO Journals

Showing 1 – 20 of 22

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

Modulation of LOXL-1 for the treatment of exfoliation glaucoma

Andras Varadi; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3798. doi:

ARVO Annual Meeting Abstract July 2019

Evaluation of treatment for traumatic optic neuropathy

Boglarka Racz; Pavel Iserovich; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2262. doi:

ARVO Annual Meeting Abstract July 2019

Modulation of phototransduction by RBP4 antagonists for treatment of diabetic retinopathy

Konstantin Petrukhin; Andras Varadi; Boglarka Racz

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2786. doi:

ARVO Annual Meeting Abstract July 2018

A Novel non-Retinoid RPE65 Inhibitor CU239 Prevents Light-Induced Degeneration of the Mouse Retina through Slowing of the Visual Cycle

Gennadiy P Moiseyev; Younghwa Shin; Yusuke Takahashi; Konstantin Petrukhin; Jian-Xing (Jay) Ma

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5330. doi:

ARVO Annual Meeting Abstract June 2017

Evaluation of the advanced antagonist of Retinol-Binding Protein 4 in animal models of bisretinoid and retinaldehyde toxicity

Konstantin Petrukhin; Boglarka Racz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1937. doi:

ARVO Annual Meeting Abstract June 2017

Evaluation of LOXL-1 as a potential diagnostic and therapeutic target in exfoliation glaucoma

Andras Varadi; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4602. doi:

ARVO Annual Meeting Abstract June 2017

Effect of the advanced non-retinoid RBP4 antagonist on vascular permeability in the mouse diabetic retinopathy model

Boglarka Racz; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5799. doi:

ARVO Annual Meeting Abstract September 2016

Ocular safety of the optimized RBP4 antagonist developed for treatment of Stargardt disease and dry AMD

Boglarka Racz; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1121. doi:

ARVO Annual Meeting Abstract September 2016

Pharmacological normalization of the complement system dysregulation in the animal model of enhanced lipofuscin formation.

Konstantin Petrukhin; Boglarka Racz

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):277. doi:

ARVO Annual Meeting Abstract June 2015

Potential treatment candidate for Stargardt disease and dry AMD

Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5472. doi:

ARVO Annual Meeting Abstract June 2015

Unusual pharmacodynamics of the optimized RBP4 antagonist in dogs

Boglarka Racz; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2473. doi:

ARVO Annual Meeting Abstract April 2014

Identification and in vitro Characterization of Novel Non-retinoid RPE65 Inhibitors

Gennadiy P Moiseyev; Jian-Xing Ma; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3477. doi:

ARVO Annual Meeting Abstract April 2014

Pharmacodynamics and pharmacokinetics study of novel non-retinoid RBP4 antagonists

Boglarka Racz; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1955. doi:

ARVO Annual Meeting Abstract April 2014

Two functional classes of RBP4 antagonists with distinct mechanisms of serum retinol lowering

Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1426. doi:

Biochemistry and Molecular Biology April 2014

In Vivo Effect of Mutant ELOVL4 on the Expression and Function of Wild-Type ELOVL4

PDF

Nawajes A. Mandal; Julie-Thu A. Tran; Lixin Zheng; Joseph L. Wilkerson; Richard S. Brush; Joel McRae; Martin-Paul Agbaga; Kang Zhang; Konstantin Petrukhin; Radha Ayyagari; Robert E. Anderson
TAGS: fatty acids, polyunsaturated fatty acid, mice, proteins, retina, skin, mutant proteins
Invest. Ophthalmol. Vis. Sci.. 2014; 55(4):2705-2713. doi: 10.1167/iovs.13-13198

ARVO Annual Meeting Abstract June 2013

Evaluation of different classes of RBP4 antagonists as potential treatments for AMD

Nicoleta Dobri; Qiong Qin; Jian Kong; Rando Allikmets; Janet Sparrow; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1703. doi:

Translational Research January 2013

A1120, a Nonretinoid RBP4 Antagonist, Inhibits Formation of Cytotoxic Bisretinoids in the Animal Model of Enhanced Retinal Lipofuscinogenesis

PDF

Nicoleta Dobri; Qiong Qin; Jian Kong; Kazunori Yamamoto; Zhao Liu; Gennadiy Moiseyev; Jian-xing Ma; Rando Allikmets; Janet R. Sparrow; Konstantin Petrukhin
TAGS: fenretinide, lipofuscin, animal model, retinoids, mice, retina, vitamin a, antagonists
Invest. Ophthalmol. Vis. Sci.. 2013; 54(1):85-95. doi: 10.1167/iovs.12-10050

ARVO Annual Meeting Abstract March 2012

Identification of a New Class of Non-Retinoid RBP4 Antagonists

Nicoleta Dobri; Xiaoming Xu; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3349. doi:

ARVO Annual Meeting Abstract March 2012

NR2E3, A Retina-specific Nuclear Receptor, Directly Regulates Transcription Of The Antioxidant Enzyme PON1

Qiong Qin; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6473. doi:

ARVO Annual Meeting Abstract April 2011

Development And Optimization Of The Htrf Assay For Antagonists Of Retinol-dependent Rbp4-ttr Interaction

Nicoleta Dobri; Konstantin Petrukhin

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5475. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Modulation of LOXL-1 for the treatment of exfoliation glaucoma

Evaluation of treatment for traumatic optic neuropathy

Modulation of phototransduction by RBP4 antagonists for treatment of diabetic retinopathy

A Novel non-Retinoid RPE65 Inhibitor CU239 Prevents Light-Induced Degeneration of the Mouse Retina through Slowing of the Visual Cycle

Evaluation of the advanced antagonist of Retinol-Binding Protein 4 in animal models of bisretinoid and retinaldehyde toxicity

Evaluation of LOXL-1 as a potential diagnostic and therapeutic target in exfoliation glaucoma

Effect of the advanced non-retinoid RBP4 antagonist on vascular permeability in the mouse diabetic retinopathy model

Ocular safety of the optimized RBP4 antagonist developed for treatment of Stargardt disease and dry AMD

Pharmacological normalization of the complement system dysregulation in the animal model of enhanced lipofuscin formation.

Potential treatment candidate for Stargardt disease and dry AMD

Unusual pharmacodynamics of the optimized RBP4 antagonist in dogs

Identification and in vitro Characterization of Novel Non-retinoid RPE65 Inhibitors

Pharmacodynamics and pharmacokinetics study of novel non-retinoid RBP4 antagonists

Two functional classes of RBP4 antagonists with distinct mechanisms of serum retinol lowering

In Vivo Effect of Mutant ELOVL4 on the Expression and Function of Wild-Type ELOVL4

Evaluation of different classes of RBP4 antagonists as potential treatments for AMD

A1120, a Nonretinoid RBP4 Antagonist, Inhibits Formation of Cytotoxic Bisretinoids in the Animal Model of Enhanced Retinal Lipofuscinogenesis

Identification of a New Class of Non-Retinoid RBP4 Antagonists

NR2E3, A Retina-specific Nuclear Receptor, Directly Regulates Transcription Of The Antioxidant Enzyme PON1

Development And Optimization Of The Htrf Assay For Antagonists Of Retinol-dependent Rbp4-ttr Interaction

To View More...

You must be signed into an individual account to use this feature.